Aravindhan Veerapandiyan
Associate Professor
University of Arkansas for Medical Sciences
faculty
Peds Pediatrics, College of Medicine
Research Areas
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Aravindhan Veerapandiyan's research investigates genetic and neurological disorders, with a focus on therapeutic interventions and molecular mechanisms. His work includes the study of gene therapy for Duchenne muscular dystrophy, as demonstrated by his involvement in the EMBARK phase 3 randomized trial. Veerapandiyan also studies treatments for spinal muscular atrophy, including an expanded access program for risdiplam. His publications address the molecular dysregulation in Autism Spectrum Disorder and the role of Semaphorin-Plexin signaling in X-linked intellectual disability syndromes. Additionally, his research explores the implementation of pharmacogenomics testing and the incidence of PANDAS and PANS in primary care settings.
Veerapandiyan has a scholarly record with an h-index of 19, 122 total publications, and 1,289 citations. He collaborates with several researchers at the University of Arkansas for Medical Sciences, including Akilandeswari Aravindhan, Murat Gökden, Pritmohinder S. Gill, and Jeffery L. Clothier.
Metrics
- h-index: 19
- Publications: 122
- Citations: 1,289
Selected Publications
- Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy (2025) DOI
- Gaps in the Assessment and Care of Neurodevelopmental and Psychiatric Conditions Associated With Dystrophinopathy (2024) DOI
- Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance (2024) DOI
- The <scp>BELS</scp> questionnaire: A novel screening tool for neurodevelopmental and psychiatric symptoms in pediatric dystrophinopathy (2024) DOI
- Charcot‐Marie‐Tooth disease in children (2024) DOI
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial (2024) DOI
- Editorial: Pediatric autoimmune neuropsychiatric syndrome (2024) DOI
- Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians (2024) DOI
- Revolutionizing neuromuscular disorders rehabilitation: The virtual reality edge (2024) DOI
- Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening (2024) DOI
- Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy (2024) DOI
- Estimate of the incidence of PANDAS and PANS in 3 primary care populations (2023) DOI
- Epilepsy Characteristics in Duchenne and Becker Muscular Dystrophies (2023) DOI
- Autosomal Recessive Spastic Ataxia of Charlevoix–Saguenay due to Novel Mutations in the <i>SACS</i> Gene (2022) DOI
- Miyoshi Muscular Dystrophy Due to Novel Splice Site Variants in <i>DYSF</i> Gene (2022) DOI
Grants & Funding
- Clinical Neurobehavioral Screening Tool for Duchenne and Becker Muscular Dystrophy UAMS ACHRI Flow Through Principal Investigator
- No FP attached UAMS ACHRI Flow Through Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics